IP Library Patent Application 10989010
Patent Application
App. No. 10/989,010

Novel enantiomeric compounds for treatment of cardiac arrhythmias and methods of use

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/989,010
Abstract

The subject invention pertains to novel enantiomerically pure compounds, and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns a method of making and purifying the compounds. The enantiomerically purified compounds, and compositions of these compounds, exhibit unexpectedly distinct and advantageous characteristics, such as a markedly superior ability to reduce or inhibit ventricular premature beats, as compared to racemic mixtures of the compounds.

Claims (42)

1 . (canceled)

2 . A method for preparing compounds of the formula

or pharmaceutically acceptable salts thereof, wherein

X 1 and X 2 may be the same or different and are selected from the group consisting of iodine, fluorine, bromine, and chlorine;

m is from 0-10; and

R 2 and R 3 may be the same or different and are each selected from the group consisting of C 1-20 alkyl, C 2-20 alkenyl, aryl, C 1-20 alkyl-aryl, C 2-20 alkenyl-aryl, heteroaryl, C 1-20 alkyl-heteroaryl, C 2-20 alkenyl-heteroaryl, cycloalkyl, heterocycloalkyl, C 1-20 alkyl-heterocycloalkyl, and C 1-20 alkyl-cycloalkyl, any of which may be, optionally, substituted with a moiety selected from the group consisting of C 1-6 alkyl, halogen, CN, NO 2 , and sO 2 ,

the method comprising

a) reacting methyl benzofuran-2-acetate with

in the presence of a Lewis acid to generate a compound of the formula 6:

b) reacting the compound of formula 6 with a Lewis acid and tetrabutylammonium iodide to form a compound of formula 7:

c) halogenating the compound of formula 7 to generate a compound of formula 8:

d) reacting the compound of formula 8 with an alcohol to form a compound of formula 9:

e) converting the compound of formula 9 into the final product.

2 . A method according to claim 1 , wherein X 1 and X 2 are both iodo.

3 . A method according to claim 1 , wherein

R 2 and R 3 may be the same or different and are each selected from the group consisting of C 1-2 alkyl, vinyl, 1-propenyl, 1- and 2-butenyl, 2-methyl-2-propenyl, phenyl, naphthyl, C 1-2 alkyl-phenyl, C 1-2 alkyl-naphthyl, vinyl-phenyl, 1-propenyl-phenyl, 1- and 2-butenyl-phenyl, 2-methyl-2-propenyl-phenyl, C 1-2 alkyl-naphthyl, vinyl-naphthyl, 1-propenyl-naphthyl, 1- and 2-butenyl-naphthyl, 2-methyl-2-propenyl-naphthyl, furanyl, thienyl, pyridyl, indolyl, quinolyl, C 1-2 alkyl-furanyl, C 1-2 alkyl-thienyl, C 1-2 alkyl-pyridyl, C 1-2 alkyl-indolyl, C 1-2 alkyl-quinolyl, (vinyl, 1-propenyl, 1- and 2-butenyl, or 2-methyl-2-propenyl)-furanyl, (vinyl, 1-propenyl, 1- and 2-butenyl, or 2-methyl-2-propenyl)-thienyl, (vinyl, 1-propenyl, 1- and 2-butenyl, or 2-methyl-2-propenyl)-pyridyl, (vinyl, 1-propenyl, 1 - and 2-butenyl, or 2-methyl-2-propenyl)-indolyl, (vinyl, 1-propenyl, 1- and 2-butenyl, or 2-methyl-2-propenyl)-quinolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, indanyl, tetrahydronaphthyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, indolinyl, tetrahydroquinolinyl, C 1-2 alkyl-azetidinyl, C 1-2 alkyl-pyrrolidinyl, C 1-2 alkyl-tetrahydrofuranyl, C 1-2 alkyl-piperidinyl, C 1-2 alkyl-indolinyl, C 1-2 alkyl-tetrahydroquinolinyl, and C 1-2 alkyl-cyclopropyl, C 1-2 alkyl-cyclobutyl, C 1-2 alkyl-cyclopentyl, C 1-2 alkyl-cyclohexyl, C 1-2 alkyl-indanyl, C 1-2 alkyl-tetrahydronaphthyl, any of which may be, optionally, substituted with a moiety selected from the group consisting of C 1-6 alkyl, halogen, CN, NO 2 , and SO 2 .

4 . A method according to claim 1 , wherein m is 1.

5 . A method according to claim 1 , wherein

X 1 and X 2 are both iodo;

R 2 and R 3 are both methyl; and

m is 1.

6 . A method according to claim 1 , wherein the Lewis acid used in step a) is tin (IV) chloride.

7 . A method according to claim 1 , wherein the Lewis acid used in step b) is aluminum iodide.

8 . A method according to claim 1 , wherein the halogenation of step c) is performed with potassium carbonate and iodine.

9 . A method according to claim 1 , wherein the alcohol used in the conversion of compound 8 to compound 9 is (R)-3-methyl-2-butanol.

10 . A method according to claim 1 , wherein the alcohol used in the conversion of compound 8 to compound 9 is (S)-3-methyl-2-butanol.

11 . A method according to claim 1 , wherein the alcohol used in the conversion of compound 8 to compound 9 is (R)-2-butanol.

12 . A method according to claim 1 , wherein the alcohol used in the conversion of compound 8 to compound 9 is (S)-2-butanol.

13 . A method according to claim 1 , wherein the conversion of the compound of formula 8 to a compound of formula 9 is accomplished in the presence of diethylaminoethyl chloride, diethylaminoethyl chloride hydrochloride, or a mixture thereof.

14 . A method according to claim 1 , wherein

the Lewis acid used in step a) is tin (IV) chloride;

the Lewis acid used in step b) is aluminum iodide;

the halogenation of step c) is performed with potassium carbonate and iodine; and

the conversion of the compound of formula 8 to a compound of formula 9 is accomplished in the presence of diethylaminoethyl chloride, diethylaminoethyl chloride hydrochloride, or a mixture thereof.

15 . A method according to claim 5 , wherein

the Lewis acid used in step a) is tin (IV) chloride;

the Lewis acid used in step b) is aluminum iodide;

the halogenation of step c) is performed with potassium carbonate and iodine; and

the conversion of the compound of formula 8 to a compound of formula 9 is accomplished in the presence of diethylaminoethyl chloride, diethylaminoethyl chloride hydrochloride, or a mixture thereof.

16 . A method according to claim 1 , wherein the product is prepared in at least about 90% enantiomeric excess.

17 . A method according to claim 14 , wherein the product is prepared in at least about 90% enantiomeric excess.

18 . A method according to claim 15 , wherein the product is prepared in at least about 90% enantiomeric excess.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2005
From: DRUZGALA, PASCAL J.; MILNER, PETER G.
To: ARYX THERAPEUTICS, INC.
Reel/Frame 016389/0223 →